SouthernWorldwide.com – Experts suggest that utilizing GLP-1 medications for weight loss might lead to an unexpected improvement in male fertility.
This week at ENDO 2026, the Endocrine Society’s annual conference in Chicago, research was presented that delves into the strong connection between obesity and male fertility issues.
Excess body weight can disrupt the hypothalamic-pituitary-gonadal (HPG) axis, which is the hormonal system responsible for regulating testosterone production. This disruption can lead to functional hypogonadism, a condition characterized by abnormally low testosterone levels due to faulty hormone signaling. These hormonal imbalances can also negatively impact sperm quality.
WEIGHT-LOSS MEDICATIONS COULD IMPACT SEXUAL HEALTH IN UNEXPECTED WAYS
Researchers analyzed data from men aged 18 to 65 who were undergoing treatment with GLP-1 weight-loss drugs. The study aimed to understand how these medications affect reproductive hormones and metabolic health, as indicated in a press release.
A comprehensive review of five randomized controlled trials was conducted. The focus was on measuring testosterone levels, the brain hormones involved in testosterone and sperm production, and a specific protein in the blood that carries sex hormones. Additionally, the study evaluated semen quality, body weight and Body Mass Index (BMI), cholesterol levels, and blood sugar.
The findings indicate that GLP-1 medications do not suppress male hormones. In fact, men with obesity and low testosterone linked to their weight may experience an enhancement in testosterone levels, improved sperm quality, and better metabolic health, particularly as they lose weight.
In one particular four-week study, the drug dulaglutide did not show any significant alterations in reproductive hormones or sexual function.
In a separate 16-week trial involving liraglutide, improvements were observed in hormonal profiles of obese men diagnosed with functional hypogonadism, suggesting that their low testosterone was likely a consequence of obesity. The review concluded that liraglutide offered superior health outcomes compared to hormone replacement therapy.
CLICK HERE FOR MORE HEALTH STORIES
Another study utilizing liraglutide reported an increase in sperm concentration and count.
A 24-week trial featuring semaglutide, commercially known as Ozempic and Wegovy, demonstrated improvements in sperm morphology and reductions in “bad” cholesterol, while maintaining total testosterone levels.
Given that the analysis included only five trials, the limited evidence base suggests that further research is essential to confirm these associations.
In their abstract, the authors summarized that GLP-1s “do not appear to acutely suppress the male HPG axis and may improve reproductive hormones and semen parameters in obese hypogonadal men, largely within the context of weight loss.”
They further noted, “However, evidence remains limited and heterogeneous, underscoring the need for larger RCTs explicitly powered to assess male reproductive outcomes.”
“This provides early evidence that GLP-1 medications taken by obese men with hypogonadism/low testosterone (low T) improves testosterone levels,” stated one expert.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
While acknowledging the need for more extensive research, Dr. Pupolo, who was not directly involved in this study, expressed optimism regarding the potential role of GLP-1s in enhancing male fertility.
“If this finding continues to gain evidence, GLP-1s might be a better option for low T than testosterone replacement therapy (TRT) in obese men – as GLP-1 medications preserve fertility, whereas TRT tends to be harmful to male reproductive/sperm function,” he added.
